Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1826]

ESMO 2021: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Enzalutamide plus androgen deprivation therapy prolongs survival in men with...

Prof Andrew Armstrong - Duke University, Durham, USA

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Exceptional response to oral metronomic chemotherapy in a rare case of...

Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT)...

Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple...

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally...

Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

More from ecancer